We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Randox Laboratories

Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmac... read more Featured Products: More products

Download Mobile App




Urine Testing Differentiates Glomerular from Tubulointerstitial Diseases on Kidney Biopsy

By LabMedica International staff writers
Posted on 22 Apr 2022
Print article
Image: Randox Daytona RX chemical analyzer (Photo courtesy of Gemini BV)
Image: Randox Daytona RX chemical analyzer (Photo courtesy of Gemini BV)

Histological examination of kidney biopsy tissue can help differentiate between glomerular and tubulointerstitial diseases, as well as differentiate between their underlying etiologies and subtypes.

Several clinical urine tests are available to differentiate between glomerular and tubulointerstitial diseases. Clinically available tests include urinalysis, urine sediment microscopy, and urine albumin, which can indicate glomerular damage via features such as urinary presence of isomorphic or dysmorphic red blood cells (RBCs) and casts, or presence of proteinuria or albuminuria.

Clinical Scientists at the Yale School of Medicine (New Haven, CT, USA) and their colleagues enrolled patients scheduled to undergo a clinically indicated kidney biopsy at two Yale-affiliated hospitals from January 2015 to June 2018. Urine samples were collected during the outpatient biopsy procedure visit or during inpatient hospitalization. The team performed urine dipstick analysis using Clinitek Status analyzer (Siemens Healthcare Diagnostics Inc., Tarrytown, NY, USA) which reported specific gravity, pH, protein, ketone, blood, and leukocyte levels on an ordinal scale.

The team also performed urine sediment microscopy (Laxco LMC4BF, Mill Creek, WA, USA) and took representative pictures at 10× and 40× magnification, which were analyzed and reported by a trained nephrologist on an ordinal scale including RBCs, RBC casts, dysmorphic RBCs, WBCs, WBC casts, renal tubular epithelial (RTE) cells, RTE casts, and granular casts. The investigators measured urine albumin and creatinine measurements using Randox RX Daytona machine (Crumlin, UK) and the other urine biomarkers using manufacturer-validated panels using the Mesoscale Discovery platform (Rockville, MD, USA).

The scientists reported that of the final 359 participants, 121 (34%) had a histological diagnosis of glomerular disease, 89 (25%) had tubulointerstitial disease, and 149 (42%) had mixed glomerular and tubulointerstitial disease. Compared to patients with tubulointerstitial diseases, those with glomerular diseases had more dipstick hematuria (3+ versus 1+) and urine albumin (1.25 versus 0.09 mg/mg). Patients with glomerular diseases had higher levels of tubular health biomarkers (Uromodulin, 1.22 versus 0.92). In a multivariable model, higher urine albumin, dipstick blood, and urine uromodulin were independently associated with higher odds of glomerular diseases (test set AUC, 0.81).

The authors conclude that urine tests, including urine albumin, dipstick blood, and urine uromodulin, was associated with the histological diagnosis of glomerular disease. These findings can help clinicians differentiate between glomerular and tubulointerstitial diseases and guide clinical decisions regarding a kidney biopsy. The study was published on April 11, 2022 in the journal Practical Laboratory Medicine.

Related Links:
Yale School of Medicine 
Siemens Healthcare Diagnostics 
Laxco 
Randox 
Mesoscale Discovery 

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Blood Gas and Chemistry Analysis System
Edan i500
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.